15 results
DEFM14A
LABP
Landos Biopharma Inc
25 Apr 24
Proxy related to merger
5:07pm
(“LianBio”) to Landos on future net sales of NX-13 in China and select Asian markets and (ii) mid-single-digit royalties payable to Landos on future net … ) milestones and tiered low-double-digit royalties to be paid by LianBio to Landos on future net sales of NX-13 in China and select Asian markets and (ii
PREM14A
LABP
Landos Biopharma Inc
15 Apr 24
Preliminary proxy related to merger
5:18pm
-digit royalties to be paid by LianBio Respiratory Limited (“LianBio”) to Landos on future net sales of NX-13 in China and select Asian markets and (ii … sales of NX-13 in China and select Asian markets and (ii) mid-single-digit royalties payable to Landos on future net sales of BT-11 and assumes
8-K
EX-99.1
LABP
Landos Biopharma Inc
4 Jan 24
Regulation FD Disclosure
8:05am
and potential commercialization rights of NX-13 in China and select Asian markets licensed to LianBio; Research collaboration with Johns Hopkins … -13 clinical development in UC; Development and potential commercialization rights of NX-13 in China and select Asian markets licensed to LianBio
8-K
EX-99.2
LABP
Landos Biopharma Inc
12 May 23
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
8:40am
clinical development in UC; Development and potential commercialization rights of NX-13 in China and select Asian markets licensed to LianBio; Research
PRE 14A
pk9b a7wdyl9wtm7ji4
10 Apr 23
Preliminary proxy
4:20pm
DEF 14A
yx2 g288hoip
28 Apr 22
Definitive proxy
4:16pm
8-K
EX-99.1
5nc rw3cfeddnx
2 Aug 21
Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates
4:02pm
8-K
EX-99.1
756hyzm vp
14 Jun 21
Regulation FD Disclosure
5:09pm
8-K
EX-99.1
y2julbjiqfzzh
17 May 21
Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates
9:23am
8-K
EX-99.2
to18vio74xp
17 May 21
Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates
9:23am
- Prev
- 1
- Next